
Conference Coverage
about 23 hours ago
SLEEP 2026 Annual Meeting Highlights Past and Future of Sleep Medicineabout 24 hours ago
Flatiron’s AI-Driven Telescope Makes Data Access More User-FriendlyLatest Content

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

How Upstream Biologics Could Transform CRSwNP Care: Joseph K. Han, MD

Familial Pulmonary Fibrosis Linked to Faster Lung Function Decline, UIP Pattern

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care

Shorts










Podcasts
Center on Health Equity & Access
All News

Structured CHE diagnosis improves outcomes: a multicenter CRF clarifies causes for most patients with chronic hand eczema, addressing diagnosis challenges and guiding targeted care.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Patients with early relapsing multiple sclerosis (MS) were able to switch to ocrelizumab after suboptimal responses to other disease-modifying therapies.

New formulations make topical retinoids for acne vulgaris and scarring more tolerable and effective, with promising data for trifarotene, tretinoin combinations, and retinols for acne.

The 2 risks operate independently so that social interventions can reduce disease risk regardless of a patient’s genetic profile.

The 2026 conference, held in Baltimore, Maryland, offered expert insight into the past and future of sleep medicine.

Two abstracts from the 2026 ASCO annual meeting shed light on who is living with polycythemia vera in the US and what that experience is costing them.

Canadian dermatologists propose treat-to-target benchmarks for chronic hand eczema, pairing IGA-CHE and itch scores to guide therapy and follow-up.





















